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NEMF mutations that impair ribosome-associated
quality control are associated with neuromuscular
disease
Paige B. Martin et al.#
A hallmark of neurodegeneration is defective protein quality control. The E3 ligase Listerin
(LTN1/Ltn1) acts in a specialized protein quality control pathway—Ribosome-associated
Quality Control (RQC)—by mediating proteolytic targeting of incomplete polypeptides pro-
duced by ribosome stalling, and Ltn1 mutation leads to neurodegeneration in mice. Whether
neurodegeneration results from defective RQC and whether defective RQC contributes to
human disease have remained unknown. Here we show that three independently-generated
mouse models with mutations in a different component of the RQC complex, NEMF/Rqc2,
develop progressive motor neuron degeneration. Equivalent mutations in yeast
Rqc2 selectively interfere with its ability to modify aberrant translation products with
C-terminal tails which assist with RQC-mediated protein degradation, suggesting a patho-
mechanism. Finally, we identify NEMF mutations expected to interfere with function in
patients from seven families presenting juvenile neuromuscular disease. These uncover
NEMF’s role in translational homeostasis in the nervous system and implicate RQC dys-
function in causing neurodegeneration.
https://doi.org/10.1038/s41467-020-18327-6 OPEN
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R ibosomes can stall during translation for a variety of rea-sons, such as the absence of termination codons followedby translation into the mRNA poly(A) tail (as in nonstop
mRNA) or the deficiency of charged tRNAs1,2. Ribosome stalling
is a critical problem, as it sequesters ribosomal subunits from the
translation-competent pool and, in addition, gives rise to aberrant
(incomplete) nascent polypeptide chains that are potentially toxic.
In eukaryotes, stalled ribosomes are resolved by rescue factors
that split the ribosomal subunits but leave the nascent chain still
linked to tRNA, obstructing the exit tunnel in the 60S subunit3–5.
This nascent chain-tRNA/60S aberrant structure is recognized by
nuclear export mediator factor (NEMF; Rqc2 in yeast). NEMF/
Rqc2 facilitates the recruitment of the E3 ligase LTN1 (Ltn1 in
yeast), which in turn ubiquitinates the nascent chain, leading to
its proteasomal degradation6–12. When ubiquitylation fails, Rqc2
additionally acts by catalyzing the C-terminal elongation of 60S-
anchored nascent chains with untemplated Alanine and Threo-
nine tails (CAT tails)11. An Rqc2 homolog was also found to
catalyze C-terminal tailing in bacteria, where the modification
acts as a direct proteolysis signal—a function that is likely to have
evolved as early as in the Last Universal Common Ancestor13. In
eukaryotes, the biological functions of CAT tails are not fully
understood, however recent evidence suggests that they can assist
Ltn1 by exposing Lys residues that may be buried in the ribo-
somal exit tunnel for ubiquitylation14.
We had previously reported that Ltn1 mutation causes motor
neuron degeneration in mice15. Whether neurodegeneration results
from defective RQC and whether defective RQC also contributes to
human disease remains unknown. The findings that Ltn1/LTN1
and Rqc2/NEMF work closely in RQC predicted that, if the phe-
notype of Ltn1-mutant mouse is a consequence of faulty RQC,
defective NEMF function might have a similar effect. Accordingly,
here we describe two novel mouse models with different N-ethyl N-
nitrosourea (ENU)-induced missense mutations in Nemf, as well as
a genetically engineered NEMF-deficient model, which exhibit
neurodegeneration and motor deficits. Functional analyses show
that the ENU-equivalent mutations lead to altered CAT tail
synthesis (“CATylation”) by yeast Rqc2. Finally, we describe nine
cases from seven unrelated families with neuromuscular phenotypes
harboring NEMF variants. Thus, our results provide evidence that
NEMF functions in neuronal homeostasis and that its loss causes
neurodegeneration and motor phenotypes in mice and humans.
These findings, along with the previously described Ltn1 mouse
model15, strongly point to RQC as a critical protein quality control
pathway protecting neurons against degeneration.
Results
Mouse Nemf mutations result in progressive motor pheno-
types. Through independent ENU mutagenesis screens, two
mouse lines with abnormal gait and muscle wasting were
identified as carrying homozygous mutations in Nemf: C57BL/
6J-Nemf R86S/R86S (nucleotide: A258T; protein: R86S) and C57BL/
6J-Nemf R487G/R487G (nucleotide: A1460G; protein: R487G)
(Fig. 1a, b). Henceforth, we refer to these homozygous mutant
mice as R86S and R487G, respectively.
R86S mice appear normal at birth but by 2 weeks of age exhibit
an overt motor phenotype that manifests as an abnormal waddle-
like gait (Supplementary Movie 1), as well as smaller body size
(Fig. 1a) with decreased growth rate thereafter (Fig. 1c). In
comparison, R487G mice have less marked motor defect and
growth reduction (Fig. 1b, c) and only by 10 weeks of age begin to
display abnormal gait and hindlimb wasting (Supplementary
Movie 2). Disease is progressive in both models. R86S mice die
prematurely with a median lifespan of 20 days, with 20% of the
animals living past 40 days, whereas R487G mice live past 2 years
(Fig. 1d). Both +/R487G and +/R86S (heterozygous animals)
have survival and growth rates similar to wild-type mice
(Supplementary Fig. 1a, b).
Since Nemf mutant mice exhibit abnormal gait, we further
examined their motor function. Although the latency to fall in an
inverted wire hang assay was comparable for wild-type and R86S
mice at 2 weeks of age (Supplementary Fig. 2a), by 8 weeks
surviving R86S mice were completely unable to perform the test
(Fig. 1e). R487G mice also displayed shorter latency to fall
compared to wild-type mice at 8 weeks (prior to overt phenotype
onset) but did not exhibit further progression of the defect when
examined at 55 weeks of age (Fig. 1e; Supplementary Fig. 2c).
Heterozygous +/R86S and +/R487G animals appeared unaf-
fected at all observed timepoints (Supplementary Fig. 2a–c).
Nemf R86S and R487G mice exhibit neurogenic atrophy. To
determine the cause of impaired motor function in Nemf mutant
mice, a histopathological examination of hindlimb muscle was
performed. Tissue cross-sections revealed decreased muscle fiber
size in the medial gastrocnemius (MG) muscle of 16- to 18-day-old
R86S mice compared to wild-type animals (Supplementary Fig. 3a,
b). Whereas the MG muscle of R487G mice appeared histologically
normal at 2 weeks of age (not shown), by 55 weeks of age localized,
nonuniform clusters of atrophied fibers, collagenous fibrosis, and
fatty infiltration were observed (Supplementary Fig. 3c).
To investigate the basis of the muscle atrophy, the integrity of
neuromuscular junctions (NMJ) was analyzed (Fig. 2a–f), reveal-
ing denervation and fragmentation of postsynaptic terminals in 8-
week-old R86S mice (Fig. 2a, c, f). At the same timepoint, R487G
exhibited more fully and partially occupied junctions than R86S
mice (Fig. 2b, f), correlating with the severity of their respective
motor phenotypes. Nonetheless, NMJ occupancy was already
decreased in R487G compared to wild-type mice at 8 weeks and
denervation continued to progress with age (Fig. 2d–f).
Mutant mice exhibit progressive axonal degeneration. The loss
of NMJs suggested that muscle atrophy of Nemf mutant mice had a
neurogenic origin. To investigate this possibility, we assessed the
extent of neuronal degeneration in Nemf mutants through the
analysis of myelinated axons in the femoral nerve motor branch. At
2 weeks of age, the number of axons were comparable in wild-type
and Nemf mice (Supplementary Fig. 4a) with similar overall mor-
phology and axonal diameter distribution suggesting that our
findings do not reflect a developmental defect (Fig. 2g–i, Supple-
mentary Fig. 4b, c). However, by 16–18 days, R86S mice began to
exhibit femoral motor myelinated axon loss (Supplementary Fig. 4a,
b), which by late end-stage (8 weeks of age) was further reduced
(~30%) (Fig. 2j, l, o) with a shift in axon diameter distribution
indicative of the largest fibers being most impacted (Supplementary
Fig. 4c). R487G mice also displayed a reduction of the largest dia-
meter fibers at 8 weeks of age (Fig. 2k, o, Supplementary Fig. 4c).
Although no further age-related degeneration was observed in
R487G animals (Fig. 2m–o), an age-dependent shift in axon dia-
meter distribution towards smaller fibers was observed (Supple-
mentary Fig. 4c). Heterozygous mice exhibited no axonal
degeneration, even past 2 years of age; thus, both alleles appear to
behave in a purely recessive manner (Supplementary Fig. 4d).
In contrast to peripheral neuropathies, characterized by loss of
distal axons such as those in the femoral motor nerve, motor
neuron disease can be evidenced by the loss of neuronal cell
bodies and their proximal axons, such as the lumbar ventral root
exiting from the spinal cord. To determine if mutations in Nemf
cause a purely peripheral neuropathy or also degeneration of
spinal motor axons, lumbar ventral roots (at the L4 level) were
examined for cell body-proximal axon loss. As with the distal part
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of axons, both the R86S and R487G mice exhibited loss of
proximal motor axons as early as 16–18 days (Fig. 2p,
Supplementary Fig. 5a, b). However, R487G also exhibited
further reduction of proximal axons between 8 and 55 weeks of
age (Fig. 2p, Supplementary Fig. 5c, d), while distal axons reached
terminal degeneration by 8 weeks (Fig. 2o). These results suggest
a neuronal dying-back mechanism, wherein the disease originates
distally. Consistent with a recessive phenotype, proximal L4
ventral roots also show no difference in heterozygous animals
(Supplementary Fig. 5e).
Finally, we note that, although Nemf mutant mice exhibit
axonal loss associated with motor phenotypes, the disease is not
specific to the motor system as preliminary analyses of femoral
sensory axons likewise showed a reduction in R86S (but not
R487G) animals (Supplementary Fig. 6). Thus, the more severe
R86S allele may also cause a sensorimotor neuropathy, similar to
Ltn1 mutant mice15.
NEMF-null mice exhibit an early onset neurologic phenotype.
Immunoblot analysis of brain and spinal cord extracts indicated
that the NEMF ENU mutations did not markedly affect the
steady-state levels of the mutant proteins compared to that of
the wild-type (Supplementary Fig. 7). In order to assess whether
the mutant proteins retain some function (i.e., whether they
are hypomorphic), we analyzed mice harboring a putative
NEMF-null allele. This allele, generated in the course of CRISPR
genetic modifications, has a single nucleotide insertion causing a
frameshift and premature termination (nucleotide: 296_297insT;
protein: D100GfsX6, henceforth, D106*; Supplementary Fig. 8a).
Accordingly, no full-length NEMF protein was detected in D106*
mouse tissues (Fig. 3a). D106* exhibited more severe phenotypes
than R86S or R487G mice, with an early deviation in growth and
pre-wean lethality by postnatal day 11 (Fig. 3b–d). Like R86S and
R487G, heterozygous D106* mice appear unaffected, consistent
with a recessive loss-of-function mechanism (Supplementary
Fig. 8b and data not shown). D106* mice exhibited a marked
reduction in occupied NMJs in the MG at end-of-life (Supple-
mentary Fig. 8c–e) along with a reduction in peripheral myeli-
nated axons (Fig. 3e, Supplementary Fig. 8f–i). In addition,
D106* mice display a respiratory distress phenotype at end-of-
life, evident by decreased oxygen saturation (Supplementary
Fig. 8j) and phrenic nerve degeneration (Supplementary
Fig. 8k–m). Thus, D106* exhibited earlier and more severe
neuromuscular changes than R86S and R487G animals. Together,
the above results suggest that, similar to the originally described
Ltn1 ENU mutation15, the missense Nemf ENU mutations are
hypomorphic and cause an age-dependent neurodegenerative
phenotype, whereas the complete loss-of-function of either Ltn1
or Nemf results in earlier and more severe phenotypes15.
Mouse ENU mutations perturb CATylation activity of NEMF/
Rqc2. The observation that NEMF ENU mutant proteins are
expressed at normal levels implied a defective function, so we
next investigated the molecular consequences of those mutations.
Notably, the R86S mutation maps to the NFACT-N domain—
which has been shown to mediate C-terminal tailing in organisms
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Fig. 1 Mutations in mouse Nemf lead to deficits in body weight, motor function, and lifespan. a, b A 18-day-old R86S homozygous mutant (R86S; a) and
55-week-old R487G homozygous mutant (R487G; b) mice are smaller compared to wild-type (WT) littermates. c Body weight curves of male and female
wild-type (orange squares), R487G (purple circles), and R86S mice (green triangles). Mean ± SD are indicated for each timepoint. Source data are provided
as a source data file. d Kaplan–Meier survival curves of males and females combined WT (orange line, n= 33), R86S (green line, n= 34; median survival:
20 days) and R487G (purple line, n= 10; median survival 601 days) mice. Statistical analysis was performed by Log-rank (Mantel–Cox) test with two-tailed
p value reported R86S vs. WT: p≤ 0.0001 and R487G vs. WT: p= 0.0074. eMotor function of 8-week-old WT (orange squares), R487G (purple circles),
and R86S mice (green triangles) (n= 16, 10, and 3, respectively) was measured by wire hang assay. Individual data points and mean ± SD are indicated.
Statistical analysis was performed by Kruskal–Wallis test followed by Dunn’s multiple comparisons, R487G vs. WT: p= 0.0712 (n.s.), R86S vs. WT: p=
0.0018(**), R86S vs. R487G: p= 0.1748. Source data are provided as a source data file. For growth curve (c) n per genotype per time-point: Male: WT
(n= 5, 6, 7, 6, 5 for weeks 1–6, 7, 8, 20, 55), R86S (n= 5, 4, 3 for weeks 1–2, 3–6, 7–8), R487G (n= 4, 6, 5, 3, 4, 5, 4 for weeks 2, 3, 4–6, 7, 8, 20, 55).
Female: WT (n= 4, 3, 5, 4 3,4, 5 for weeks 1, 2, 3, 4, 5, 6, 8–55), R86S (n= 3, 5, 1 for weeks 1, 2, 3–5), R487G (n= 2, 5, 3, 4, 5, 4 for weeks 2, 3, 4, 5,
6–20, 55).
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as divergent as yeast and bacteria11,13. The R86S mutation is in
the vicinity of the universally conserved, catalytic residues D96
and R97 (Fig. 4a). With regard to the R487G mutation, it maps to
the structurally adjacent second coil motif, which is also likely to
contribute to C-terminal tailing by assisting with A-site tRNA
recruitment11.
Since NEMF homologs are well conserved with regard to
sequence, structure and function and robust assays for RQC
activity are established in yeast, we utilized this model organism
for mechanistic studies. Although mammalian NEMF could not
functionally replace Rqc2 in yeast (unpublished observations), the
residues affected by the ENU mutations in mice are also
conserved in yeast (Fig. 4a, Supplementary Fig. 9) so the
equivalent mutations were introduced in Rqc2 (R88S and
K534G, respectively; Fig. 4a). The equivalent residue of NEMF’s
universally conserved D96 in yeast is D98 (Fig. 4a), which was
mutated to Tyr16. Rqc2 R88S, K534G, and D98Y mutant levels
were comparable to the wild-type protein (Fig. 4b–f).
To investigate the effect of the ENU mutations in C-terminal
tailing by Rqc2, we used Ltn1-deficient yeast, since, as previously
reported, in ltn1Δ cells a ribosome stalling reporter became
readily modified with CAT tails (as evidenced by the formation of
a smeared band immediately above the unmodified reporter
band; Fig. 4b, c, lanes 2)11,16,17. As also reported, CATylation was
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strictly dependent on Rqc211,16–18: this modification was
abolished in Ltn1- and Rqc2-double deficient cells (Fig. 4b, c,
lanes 3) and could be restored by expression of Rqc2 wild-type
(lanes 4), but not by a rationally designed, CATylation-deficient
D98Y mutant (lanes 5)16. As predicted by the hypothesis, Rqc2
ENU mutants were also defective in CATylation in this assay,
although only partially (lanes 6–7). Furthermore, as indicated by
the ratio of modified versus unmodified species, the Rqc2 R88S
substitution caused a stronger defect in CAT tail formation in
comparison to the K534G; this finding shows a striking
correlation with the phenotypic severity of the respective mouse
alleles (Fig. 4b, c, lanes 6–7).
Importantly, additional functions of Rqc2 in RQC remained
unaffected by the ENU mutations. As previously reported,
levels of a ribosome stalling reporter were low in wild-type yeast
due to Ltn1-mediated degradation6 (Fig. 4d, lane 1 (anti-GFP))
and were increased in cells lacking Rqc2 (rqc2Δ; lane 2) likely
due to less efficient Ltn1 binding7,8,11,14,16–18. Re-expression of
Fig. 2 Nemf ENU mutations cause progressive neuromuscular degeneration. a–e Representative images of neuromuscular junction (NMJ) staining of
medial gastrocnemius (MG) muscle from mice of indicated genotypes and ages. Tissues were stained for presynaptic vesicles (anti-SV2, green),
neurofilaments (anti-neurofilament 2H3, green), and acetylcholine receptor (α-bungarotoxin, red). Unoccupied (arrow) and partially occupied (arrowhead)
junctions are highlighted. Scale bar, 60 µm. Inset scale bar, 30 µm. f Quantification of fully innervated, partially innervated or denervated NMJs based on
presynaptic and postsynaptic staining overlap. Eight-week-old WT, R487G and R86S mice (n= 4, 5, and 3 respectively), and 55-week-old WT and R487G
mice (n= 4 and 3, respectively) were analyzed. By 8 weeks R487G or R86S mice compared to WT (****p < 0.0001), but were not different from one
another (p= 0.4391). Fifty-five weeks of age, R487G vs. WT (****p < 0.0001). Data are presented as mean percent occupancy value ± SD. Statistical
analysis was performed by two-way ANOVA followed by Tukey’s multiple comparison, for % fully occupied. g–n Representative cross-sections of femoral
nerve motor branches from mice of indicated genotypes and ages. Scale bar, 20 µm. o Total myelinated axon number in cross-section of WT and Nemf
mutant mice at 8-week-old wild-type (WT), R487G and R86S mice (n= 9, 7, and 4, respectively), and 55-week-old WT and R487G mice (n= 6 and 4,
respectively). Eight weeks (WT vs. R487G ****p < 0.0001, WT vs. R86S ****p < 0.0001 and R487G vs. R86S ***p= 0.0005). Fifty-five weeks (WT vs.
R487G ****p < 0.0001. R487G 8 weeks vs. 55 weeks n.s.p= 0.9767). pMyelinated axon number in cross-sections of L4 ventral roots of WT and Nemf ENU
mice. Analysis of 8-week-old WT, R487G and R86S mice (n= 5, 3, and 4, respectively), and 55-week-old WT and R487G mice (n= 4 each). At 8 weeks of
age R487G vs. WT *p= 0.0136, R86S vs. WT ****p < 0.0001, R487G vs. R86S **p= 0.0063, by 55 weeks of age R487G vs. WT ****p < 0.0001, R487G
8 weeks vs. R487G 55 weeks **p= 0.0055. o, p Individual data points and mean ± SD are indicated. Statistical analysis was performed by one-way
ANOVA followed by Tukey’s multiple comparison (wild-type, orange squares; R487G, purple circles; R86S, green triangles). Source data for f, o, p are
provided as a source data file.
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Fig. 3 Nemf D106* mice display perinatal neurodegeneration and lethality. aWestern blot analysis of brain lysates from 10-day-old wild-type (WT), and
Nemf D106* hetero- and homozygous mice using anti-NEMF antibody, and anti-GAPDH antibody as loading control. b Eleven-day-old D106* homozygous
mice are smaller than WT littermates. Mutant mice display wasting and are unable to upright themselves at this timepoint. c Body weight of WT (green
circle, n= 8 day 1, n= 5 days 7 and 11) and D106* homozygous (purple circle, n= 4 days 1 and 7, n= 7 day 11) mice for WT vs. D106* at each 1, 7, and
11 days of age, respectively (n.s.p > 0.9999, ****p < 0.0001, ****p < 0.0001). Mean ± SD is indicated. Statistical analysis was performed by two-way
ANOVA followed by Sidak’s multiple comparison. d D106* mice have shortened lifespan. Kaplan–Meier survival curves of D106* homozygous (purple line,
n= 9; median survival: 11 days) and WT (green line, n= 9) mice p= 0.0022. Statistical analysis was performed by Log-rank (Mantel–Cox) test with two-
tailed p value reported (e), myelinated axon numbers from whole cross-sections of femoral nerve motor branches in 9- to 11-day-old WT and D106*
homozygous mice. For motor (WT: n= 3; Nemf D106*: n= 4, ****p < 0.0001) and sensory (WT: n= 3; Nemf D106*: n= 6, **p= 0.0031). Individual data
points and mean ± SD are indicated. Statistical analysis was performed by a two-sided unpaired t test. Source data for c, e are provided as a source data file.
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wild-type Rqc2 (lane 3), or the “ENU mutant” Rqc2 proteins
(lanes 5 and 6) rescued this rqc2Δ phenotype in an otherwise
wild-type background, indicating that the mutant proteins are
competent to bind to ribosomes and stabilize Ltn1 binding.
Thus the ENU mutations appear to cause a selective defect in
C-terminal tailing.
To provide further evidence for the CATylation defect of Rqc2
ENU mutants, we analyzed expected consequences of impaired
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Fig. 4 Nemf ENU mutations selectively affect the CATylation function of Rqc2. a Domain diagram and partial alignment of mouse NEMF and homologs—
human NEMF, fly Caliban, and yeast Rqc2. Sequences flanking residues affected by the ENU mutations are shown. Domains and motifs depicted: NFACT-N
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or ltn1Δ rqc2Δ cells were transformed with the GFP-R12-RFP (GRR) stalling reporter and plasmids encoding Rqc2-FLAG WT, CATylation-deficient D98Y
mutant, or ENU-equivalent mutants (R88S and K534G). Immunoblots: anti-GFP and anti-FLAG to monitor reporter and Rqc2 levels, respectively, and anti-
Pgk1 as loading control. c Strains transformed with Rqc2-FLAG and the GRR stalling reporter, as indicated. Immunoblot anti-GFP monitored reporter
modification and aggregation. d Wild-type (WT) and RQC2-deleted (rqc2Δ) cells were transformed with the GRR stalling reporter, and indicated Rqc2-
FLAG constructs and analyzed as in “b”. e Kless-K2, -K27, or -K36 reporters (see Supplementary Fig. 8) expressed in rqc2Δ cells together with Rqc2-FLAG
WT, the CATylation-deficient Rqc2 aaa mutant (Asp9, Asp98, and Arg99 mutated to Ala), or Rqc2-equivalent ENU mutants as indicated. Anti-HA and
anti-FLAG blots monitored reporter and Rqc2 expression, respectively. f As in panel “f”. Quantification of reporter levels relative to the Pgk1 internal control
from three biological replicates, individual values with means ± SEM. For each blot b–e MW markers in kDa are indicated.
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CATylation. For example, CAT tails are known to promote
nascent chain aggregation when Ltn1-mediated ubiquitylation
fails altogether16–18. Accordingly, in ltn1Δ cells (or in ltn1Δ rqc2Δ
cells expressing wild-type Rqc2), CAT tail-mediated aggregation
of a ribosome stalling reporter was conspicuous (Fig. 4c). In this
assay, both Rqc2 ENU mutants were likewise competent to
mediate reporter aggregation in ltn1Δ rqc2Δ cells; however,
consistent with these mutants’ decreased ability to make CAT
tails, aggregates were formed to a lower extent compared to wild-
type Rqc2. Similar observations were made when the formation of
endogenous aggregates were monitored by using as a readout, the
hsp40 Sis1, which becomes stably incorporated into CAT tail-
dependent aggregates16–18 (Supplementary Fig. 10a).
CATylation has been additionally implicated in facilitating
Ltn1-mediated ubiquitylation14. As expected, such a requirement
was not evident in the results of the experiment shown in Fig. 4d,
since the ribosome stalling reporter utilized in that experiment
was rich in Lys residues and was predicted to present Lys for
Ltn1-mediated ubiquitylation even in the absence of added CAT
tails14. We thus engineered an alternative reporter whose Ltn1-
mediated ubiquitylation and degradation would be dependent on
CAT tail synthesis, because the reporter lacked Lys residues
(K-less) except at two positions buried deep within the ribosomal
exit tunnel, located 2 residues N-terminal to the ribosome stalling
sequence (Kless-K2; Supplementary Fig. 10b). Consistent with a
CAT tail requirement for degradation, Kless-K2 reporter levels
(anti-HA) were indeed higher in rqc2Δ cells reconstituted with a
CATylation-deficient Rqc2 mutant (Rqc2 aaa11) compared to
Rqc2 wild-type (Fig. 4e, f). Notably, Kless-K2 levels were
intermediate in cells expressing the Rqc2 ENU mutants consistent
with those mutants’ partial CATylation defect. As controls,
reporters with Lys residues either closer to the opening of the exit
tunnel (Kless-K27) or predicted to be already exposed on the
outside (Kless-K36) were also tested. As expected, the levels of
these reporters in the presence of Rqc2 ENU mutants were low
and comparable to the Rqc2 wild-type and aaa mutant (Fig. 4e, f).
We additionally verified that all constructs were targeted for
degradation in a Ltn1-dependent manner (Supplementary
Fig. 10c). These results substantiate the model that CATylation
can function to support Ltn1-mediated ubiquitylation and suggest
that the Rqc2 ENU mutations interfere with the degradation of a
subset of Ltn1 substrates that rely on CAT tails for ubiquitylation.
NEMF variants are associated with juvenile neuromuscular
disease. Through collaboration facilitated by GeneMatcher19,
nine patients from seven unrelated families with likely pathogenic
variants in NEMF were identified. Seven patients harbored bial-
lelic variants, an eighth patient harbored an inherited variant and
a de novo variant (though the chromosomal phase is unde-
termined, i.e., whether the variants are in cis or trans) and the
ninth patient harbored a single de novo missense variant. These
patients display intellectual disability and/or early motor neuron
disease phenotypes of varying severities and progression, sum-
marized in Table 1. Detailed clinical findings are available (Sup-
plementary Note 1).
An Australian case of consanguineous Syrian parents (AUS1-
II:3, Fig. 5a–f) presented with axonal neuropathy and spastic
paraplegia at 18 months of age; the individual has severe speech
delay. Whole-genome sequencing (WGS) identified a homo-
zygous nonsense variant in NEMF (c.2608C > T, p.(Arg870*)). In
a Turkish family, (DEU1, Fig. 5a) with two individuals presenting
with developmental delay and peripheral neuropathy in child-
hood, a homozygous nonsense variant in NEMF was identified
(c.2014A > T, p.(Lys672*)). In a Persian family (IRN1, Fig. 5a), a
proband presented with hypotonia, developmental delays and
severe speech delay; WGS identified a homozygous frameshift
variant in NEMF (c.2451delA; p.(Ser817fs*7)). In a Saudi Arabian
family (SAU1, Fig. 5a) with two individuals presenting with
developmental delays, a homozygous frameshift variant in NEMF
was identified (c.2871_2875dupTGTAG; p.(Asp959fs*2)). In a
Caucasian proband (USA1-II:1, Fig. 5a) presenting with gross
developmental delay in the second year of life, two NEMF
variants were identified: a maternally inherited nonsense variant
(c.2011C > T; p.(Arg671*)) and a de novo variant of the start
codon (c.1A > T; p.(Met1?)). Chromosomal phase could not be
determined based on clinical NGS sequencing. In another
Caucasian proband (USA2-II:1, Fig. 5a), who presented with
mild hypotonia and speech delays, biallelic NEMF variants were
identified by exome sequencing: two maternally inherited
missense variants (c.980G > A;p.Arg327Gln and c.2777C > T; p.
Pro926Leu) and a paternally inherited frameshift variant
(c.2768delA; p.Lys923Argfs*27). A Caucasian proband (USA3-
II:2, Fig. 5a) who presented with axonal sensorimotor peripheral
neuropathy at 17 years of age harbored a de novo missense
variant in NEMF (c.1658T > C, p.(Ile553Thr)). The variant is
absent from gnomAD and predicted to be damaging by all
protein prediction programs utilized (CADD “score 28”;
MutationTaster, “disease causing”; PolyPhen-2, “probably dama-
ging”; Provean, “deleterious”; SIFT, “deleterious”). The substi-
tuted p.(Ile553) is conserved through evolution including in yeast
(Supplementary Fig. 9). As a second disease-associated variant
Table 1 Clinical features of affected individuals.
Family AUS1 DEU1 DEU1 IRN1 SAU1 SAU1 USA1 USA2 USA3
Individual II:3 II:3 II:6 II:1 II:1 II:2 II:1 II:1 II:2
Age (years) 7+ 7 mo 22 16 28 10+ 6mo 7 6+ 4mo 7+ 10mo 24
Sex M M F M M M F F M
Age at onset (years) 1.5 2 1 1 2 2 1.7 2 17
ID/GDD + + + + + + − + −
Speech delay + + + + + + + + +
Neuropathy (axonal) + + + N/A N/A N/A N/A N/A +
Ataxia + + + − − − − − −
Distal muscle atrophy + + + + − − − − +
Hypotonia − − + + − − + + −
Respiratory distress − − − − − − + − −
Tremor + − − N/A − − − − +
Abnormal brain imaging N/A + − N/A − − N/A + N/A
Kyphosis/Scoliosis + + + − − − + − −
ID/GDD intellectual disability/global developmental delay; − absent, + present, N/A not ascertained/not applicable.
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has yet to be identified, it is possible that the de novo p.
(Ile553Thr) variant acts alone in a dominant-negative manner.
Thus, we present eight cases from six families with biallelic,
likely pathogenic or pathogenic variants (based on American
College of Medical Genetics (ACMG) guidelines20), and a ninth
case with a milder phenotype carrying a de novo missense variant
affecting a highly conserved residue. These findings suggest
that variants in NEMF can cause neuropathy and motor
dysfunction, sometimes associated with speech delay and
intellectual disability.
Discussion
Our studies identify Nemf as a novel gene implicated in neuro-
degeneration and neuromuscular disease in mice and humans.
Moreover, this finding, along with the previously described Ltn1
mouse model15, strongly point to RQC as a critical molecular
pathway protecting neurons against degeneration. This suggests
that the presence of variants in NEMF and other RQC factors (e.g.,
Listerin) should be examined in patients with related diseases.
Our results indicate that patients with NEMF variants can
additionally manifest intellectual disability, most notably speech
delay. This conclusion is supported by a genome-wide association
analysis which included NEMF variants among several genes
potentially implicated in cognitive phenotypes21. Similarly,
mutation of GTPBP2, a GTPase that mediates the splitting of
stalled ribosomes upstream of RQC22, causes Jaberi–Elahi syn-
drome23–25, an early onset neurodegenerative disease character-
ized by dystonia, motor and sensory neuropathy, ataxia, and
cognitive dysfunction. Future experiments will address the
potential for cognitive dysfunction in Nemf mutant mice,
although we anticipate that the interpretation of such analyses
may be confounded by the presence of motor and sensory deficits.
The observation that one patient (USA3-II:2) with a hetero-
zygous variant and later onset peripheral neuropathy phenotype
may suggest potential dominant-negative impacts from variants
in NEMF. Future work will address potential modifiers and
determine if this allele could dominantly cause disease in mouse
models. Thus far, no motor or sensory peripheral degeneration
has been observed in our heterozygous mouse models at one and
a half years of age.
The observations that Rqc2 homologs from bacteria to humans
have high overall sequence and structural similarity and that
residues specifically implicated in the C-terminal tailing mod-
ification are strictly conserved (Fig. 4a, Supplementary Fig. 9;
refs. 2,11,13) strongly suggests that Rqc2 homologs across all
domains of life share a fundamental role in mediating C-terminal
tailing in RQC. In fact, this biochemical activity has been reported
for a homolog as evolutionarily distant as B. subtilis RqcH11,13.
Despite great progress made toward understanding this and other
fundamental mechanisms in RQC2, new mammalian models
have been lacking to establish the physiological relevance of the
findings and to directly test predictions regarding molecular
mechanisms of neurodegeneration. Our results now show that the
neurodegeneration-causing mouse NEMF R86S and R487G
mutations selectively interfered with yeast Rqc2’s ability to
mediate CAT tail synthesis, and that phenotypic severity is cor-
related with the extent of their reduction in CATylation activity,
thus suggesting both a link between neurodegeneration and
defective C-terminal tailing as well as a physiological role for this
RQC mechanism in mammals.
Methods
ENU Mutagenesis and mapping. The B6J-Nemf R86S line was originally derived
from an N-ethyl-N-nitrosourea mutagenesis screen for reproductive defects initi-
ated at The Jackson Laboratory26. Chemical mutagenesis was induced in a C57BL/
6J background and mutagenized mice were subsequently outcrossed to C3HeB/FeJ
(C3H). The line was then backcrossed to C57BL/6J for at least 10 generations to
obtain the B6J-Nemf R86S (JAX Stock #19392) line used in this study. The mutation
was mapped to a 4.6 Mb interval in an F2 intercross (Chr. 12: 65486719-70085250
bp, GRCm38) and the only exonic variant detected among 15 candidate genes
analyzed was in the Nemf gene. The B6J-Nemf R487G line (JAX Stock #18870) was
derived from an independent ENU mutagenesis screen for eye phenotypes in a
a b
e f
c d
Fig. 5 NEMF variants are associated with neuromuscular disease in humans. a Pedigrees of identified families having affected individuals and NEMF
variants. “−” indicates wild-type allele, “+” indicates variant allele, arrowhead indicates proband. Different font colors are used to facilitate visualization of
the distribution of wild-type (“−”) and unique mutant (“+”) alleles in the pedigrees. b–f Clinical photography of 7-year-old subject AUS1-II:3. Asymmetric
pectus excavatum, scoliosis (b), and characteristic adducted thumb posture are evident (c). Right foot showing surgical scars with residual equinovarus
foot deformity and toe clawing (d). Images showing pectus excavatum, kyphoscoliosis, hip, and knee flexor contractures with distal muscle wasting and
residual equinovarus foot posturing despite previous orthopedic surgery (e, f).
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C57BL/6J background, also at The Jackson Laboratory27. Crossing heterozygous
animals from each ENU allele produced affected offspring in an allelism test
suggesting the two mutations were in the same gene. Both strains were mapped to
Chr. 12 in F2 intercrosses26,27 and each allele was backcrossed to C57BL/6J for at
least ten generations to eliminate unlinked and distantly linked ENU-induced
mutations as potential genetic confounds. A positive allelism test between
Nemf R86S and Nemf R487G confirmed that the ENU-induced mutations were
disease-causing and were not the result of an unknown, but tightly-linked alternate
ENU mutation.
CRISPR–Cas9 mutagenesis. The NemfD106* strain (JAX Stock #34815) was
obtained from a CRISPR–Cas9 mutagenesis performed by cytoplasmic micro-
injection of C57BL/6J zygotes with Cas9 mRNA and sgRNA targeting exon 4 of
Nemf: 5′-GCTTGGTGTGGACAGAATTG-3′. Mosaic founder mice identified as
carrying a mutation in the targeted region were backcrossed to C57BL/6J. Resulting
N1 progeny identified as carrying the mutation were further backcrossed to C57BL/6J
to establish the colony.
Mouse strains, husbandry, and genotyping. All mouse husbandry and proce-
dures were reviewed and approved by the Institutional Animal Care and Use
Committee at The Jackson Laboratory were carried out according to the NIH
Guide for Care and Use of Laboratory Animals (AUS# 01006). Mice were bred and
maintained under standard conditions: an ambient room temperature of 69 °F,
humidity at 42% and a 10/14 h dark/light cycle. Tail or ear tissue was lysed in
proteinase K at 55 °C overnight and extracted DNA was used to determine gen-
otype. At The Jackson Laboratory, genotyping for B6J-Nemf R86S strain was per-
formed via PCR using the following primers: forward primer specific to wild-type
allele: 5′-AACATTTGAAGAGTCGGGGA-3′; forward primer specific to mutant
allele: 5′-AACATTTGAAGAGTCGGGGT-3′; reverse primer common for both
alleles: 5′-GCAGGTGGATGGTAGCAACG-3′. Similarly, for the genotyping of the
B6J-Nemf R487G mice the following primers were used: forward primer specific to
wild-type allele: 5′-TGCTGCTAAAAAAACCCGGA-3′; forward primer specific to
mutant allele: 5′-TGCTGCTAAAAAAACCCGGG-3′; reverse primer common for
both alleles: 5′-AAAGCCCTTGCTGCAAAGCC-3′. The following primers were
used for the genotyping of B6J-Nemf D106* strain: forward primer: 5′-CATGGTG
AATGGAGAGAACC-3′; reverse primer: 5′-TTGATCCCAGCACTAGGGAG-3′.
D106* PCR product was Sanger sequenced and assessed via chromatogram.
Phenotypic and behavioral analyses. Mice were weighed weekly from 7 ± 1 days of
age to 8 weeks, unless indicated otherwise. Longer surviving animals were additionally
weighed at 20 and 55 weeks. For the D106* mouse weight at weeks 1 and 1.5, it was
determined that there were no sex differences on the phenotypes and therefore the
data was presented as mixed sex, with similar numbers of males and females. Inverted
wire hang assay was used to assess motor function. It was determined that there were
no sex differences in phenotype and therefore the data was presented as mixed sex,
with similar numbers of males and females: mice were placed on top of a wire mesh
cage cover which was then inverted for a maximum of 60 s, and the latency to fall was
measured. Mice were allowed to rest for a minimum for 5min before repeating the
test. The average of two tests was recorded per timepoint.
Analysis of myelinated axons. Motor and sensory branches of the femoral nerve,
L4 ventral roots or phrenic nerves were dissected and fixed overnight at 4 °C in 2%
glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer. Nerves were
then post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer and embedded
in Embed 812 Resin (Electron Microscopy Sciences, Hatfield, PA). Sections mea-
suring 1 µm were cut on a Leica RM2265 rotary microtome with a diamond knife,
baked onto a glass slide, and heat stained with 0.5% aqueous toluidine blue. For
myelinated axon count and diameter analyses, images were captured using a Nikon
Eclipse E600 microscope with 40× and 100× objectives. The total number of
myelinated axons in each nerve was counted using an automated threshold method
in ImageJ (v1.52p) with manual confirmation28. With ImageJ software (v1.52p),
the Threshold function was adjusted in order to only highlight axoplasm on whole
nerve sections, and Analyze particle function was then used to quantify the number
of myelinated axons and areas of each nerve. The diameter was determined from
axonal area. It was determined that there were no sex differences in phenotype and
therefore the data was presented as mixed sex, with similar numbers of males and
females. Images of large nerves that could not be captured as a single image at 40×
magnification were generated as montages to show the whole nerve, using the
ImageJ (v1.52p) Stitching Grid/Pairwise plugin29.
Histological analysis of gastrocnemius muscle. Mice were euthanized and right
hindlimb was extracted and post-fixed in Bouin’s fixative. Whole hindlimbs were
cross-sectioned through the middle portion of lower and upper legs. The sectioned
tissues were then paraffin-embedded, sectioned, mounted, and stained with
hematoxylin and eosin for light microscopic analysis according to standard his-
tological procedures. Slides were scanned using a NanoZoomer 2.0 (Hamamatsu)
at 40× magnification. Representative images were taken from the MG region of the
lower leg, using NDP.view2 software (U12388-21, Hamamatsu).
NMJ staining and occupancy analysis. The MG muscle was dissected and fixed
in freshly prepared 2% paraformaldehyde (Electron Microscopy Sciences) in
phosphate-buffered saline (PBS) overnight. The samples were then incubated in
blocking solution (2.5% bovine serum albumin (Sigma-Aldrich) and 1%Triton-X
100 (Sigma-Aldrich) in PBS) for 1 h before they were gently teased apart and
pressed between two glass slides using a binder clip for 15 min at 4 °C. Samples
were subsequently returned to the blocking solution, permeabilized overnight at
4 °C, and incubated with primary antibodies (1:500 mouse monoclonal IgG1 anti-
neurofilament 2H3 and 1:250 anti-SV2 (DSHB) in blocking buffer) overnight at
4 °C on a slow shaker. Samples were then washed at least 4 times for 15 min in 1×
PBS and incubated overnight at 4 °C on a slow shaker with 1:500 Alexa-Fluor 488
goat anti-mouse IgG1 and 1:1000 α-bungarotoxin conjugated with Alexa-Fluor 594
(Invitrogen, Carlsbad, CA) to stain for acetylcholine receptor (AChR). After
incubation, samples were rinsed three times and washed at least four times for
15 min each, mounted in 80% glycerol and imaged using an SP5 Leica confocal
microscope. Occupancy of 50 or greater randomly selected NMJs was scored
blinded to genotype on a Nikon E600 fluorescence microscope. Full occupancy of
NMJ was defined as when presynaptic nerve staining fully overlaid with AChR,
partial occupancy as when positive for AChR but only partially stained for pre-
synaptic nerve, and denervation as when positive for AChR but negative for pre-
synaptic nerve staining. It was determined that there were no sex differences in
phenotype and therefore the data was presented as mixed sex, with similar num-
bers of males and females. Images were obtained on a Leica SP5 or SP8 laser-
scanning confocal microscope with a 40× or 63× objective lens. Z stacks were
collapsed into projected images and merged using FIJI (v1.52p)30 (NIH, http://rsb.
info.nih.goc/ij/).
Oxygen saturation measurements. The MouseOxTM Pulse-oximeter (Starr Life
Sciences, Oakmont PA) was used to measure SpO2 on 10- and 11-day-old D106*
mice and unaffected littermates. It was determined that there were no sex differ-
ences in phenotype and therefore the data was presented as mixed sex, with similar
numbers of males and females. Mice were measured in a darkened room and held
until calm, before placing the extra-small collar probe on the neck with the reading
window near the carotid artery. Readings were taken for approximately 2–10 min
from each mouse. Readings were sorted by Excel spreadsheet and R, for readings
that had no SpO2 error codes in a block.
S. cerevisiae strains and constructs. Strains used in this work are isogenic to
BY474116. The GFP-Arg12-RFP (referred to as GRR) construct was a gift of J.
Weissman (UCSF)7. To generate Rqc2 constructs, the coding sequence of Sac-
charomyces cerevisiae RQC2 was amplified by PCR with the 3× FLAG epitope
added at the C-terminus, and cloned into the YCplac111 vector (LEU2 marker,
CEN, and GPD promoter)16. Point mutations were inserted by site directed
mutagenesis or by gene synthesis. To generate the Rqc2 aaa mutant11, a gene
fragment was synthesized to contain the first 181 amino acids of Rqc2 with D9A,
D98A, and R99A mutations flanked with 5′ PstI and 3′ SpeI restriction sites (IDT).
The gene fragment was subcloned into the Rqc2-3× FLAG construct by digestion
with SpeI and PstI followed by triple ligation. The Kless-K2, -K27, and -K36
reporters were generated by inverse PCR of the HA-Kless GFP-R12 construct16 to
introduce additional Lys-Ala-Gly-Lys (AAAGGTGCTAAA) sequences in amino
acid positions 2, 27, and 36 N-terminal of the R12 stalling signal.
Protein expression analyses. Yeast total soluble extracts were prepared from cells
that were flash frozen in liquid nitrogen and lysed with glass beads under dena-
turing conditions. Protein quantitation was performed by the BCA method.
Totally, 7.5–30 µg of protein extract were resuspended in sample buffer (1%
sodium dodecyl sulfate, 0.005% bromophenol blue, 5% glycerol, 50 mM dithio-
threitol, 50 mM Tris-Cl (pH 6.8)) and incubated at 100 °C for 5 min. Protein
samples were run on Novex or Novus gels (Invitrogen), transferred onto poly-
vinylidene fluoride (PVDF) membrane and immunoblotted for anti-FLAG tag
(M2, Sigma, 1:1000), anti-HA (3E10, Roche. 1:1000), anti-GFP (Roche clone 7.1
and 13.1, 1:1000), anti-Pgk1 (Invitrogen clone 22C5D8, 1:10,000) and anti-Sis1
(E. Craig31, 1:10,000-20,000). Blots corresponding to yeast work (Fig. 4b–e, Sup-
plementary Fig. 10a, c) are available uncropped in Supplementary Figs. 11 and 12.
For mouse experiments, spinal cord and brain were collected immediately
following cervical dislocation, snap-frozen in liquid nitrogen and stored at −80 °C.
Tissues were homogenized in lysis buffer (20 mM Tris-HCl (pH7.5), 150 mM
NaCl, 5 mM EDTA (pH8), protease inhibitor (Complete Protease Inhibitor
Cocktail, Roche)) on TissueLyserII (Qiagen), incubated in 0.5% NP-40 for 30 min
at 4 °C, and precleared at 12,000 RCF for 20 min. Protein concentrations were
determined by BCA method. Protein samples were boiled in sample buffer and
were run on ExpressPAGE gels (Gene Script), transferred onto PVDF membrane
and immunoblotted with anti-NEMF (Proteintech, 11840-1-AP, 1:1000) and anti-
GAPDH (14C10, Cell Signaling,1:20,000) antibodies. Immunoblots were developed
using ECL reagent (Thermo Fisher, GE healthcare) and imaged in LAS 4000
Imager or on X-ray film. Uncropped blots from Fig. 3a and Supplementary Fig. 7
are available in Supplementary Figs. 11 and 12.
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Sequence alignment. Amino acid sequences were aligned using CLUSTAL W
(V2.1)32 and files were generated by Strap software (September 2012 version)33.
Sequence similarity was calculated using the Sequence Manipulation Suite(V2.0)34.
Alignment plot was generated by PLALIGIN(V2.0)35.
Ethics approval. The participants in this study were identified through the Gene-
Matcher database19 where clinicians and researchers with variants in genes can
identify groups with similar genotype/phenotype findings and collaborate. Informed
consent was obtained from all individuals included in the study. Approval for the
studies have been from the following: The Institutional Review Board (IRB) at Baylor
College of Medicine (protocol number H-29697); considered IRB exempt at the
University of South Florida and Mission Fullerton Genetics Center; The Australian
Genomics Neuromuscular Disorders ethics committee approval from Melbourne
Health (HREC/16/MH251); approval from the ethics commission of Otto-von-
Guericke-Universität and the Medizinischen Fakultät at Universitätsklinikum
Magdeburg A.ö.R.; the IRB at The University college London; the IRB at King Fahad
Medical City (IRB#19-512). The authors affirm that human research participants
provided informed consent for the publication of the images in Fig. 5b.
Patient DNA sequencing
USA1 and USA2. Exons and flanking splice junctions were captured from genomic
DNA using the IDT xGen Exome Research Panel v1.0. Massively parallel
sequencing (NextGen) was performed on an Illumina system with 100 bp or
greater paired-end reads. Reads were aligned to human genome build GRCh37/
UCSC hg19, and analyzed for sequence variants using a custom-developed analysis
tool. Whole-exome sequencing (WES) data for all sequenced family members was
analyzed using GeneDx’s XomeAnalyzer. This includes nucleotide and amino acid
annotations, population frequencies (NHLBI Exome Variant Server, 1000 Gen-
omes, and internal databases), in silico prediction tools, amino acid conservation
scores, and mutation references. The identified variants were filtered based on
inheritance patterns, variant type, gene lists of interest developed internally, phe-
notype, and population frequencies, as appropriate36. The general assertion criteria
for variant classification are publicly available on the GeneDx ClinVar submission
page37.
USA3Clinical exome sequencing was carried out at Baylor Genetics
Laboratories as part of the clinical work up and his parents’ DNAs were sequenced
at the Human Genome Sequencing Center at Baylor College of Medicine as part of
the Baylor-Hopkins Center for Mendelian Genomics (BHCMG) research initiative.
Briefly, genomic DNA underwent exome capture with Baylor College of Medicine
Human Genome Sequencing Center core design (52Mb, Roche NimbleGen, RRID:
nif-0000-31466), and were sequenced on the HiSeq platform (Illumina) with
∼100× depth of coverage. Using the Mercury in-house bioinformatics pipeline,
sequence data was aligned and mapped to the human genome reference sequence
(hg19)38.
AUS1. Whole genome sequencing (Illumina HiSeq) of the proband was performed
at Kinghorn Center for Clinical Genetics, Garvan Institute of Medical Research.
Data were analyzed using the Seave bioinformatic analysis pipeline39.
DEU1. WES was performed with leukocyte genomic DNA from both affected
children using the capture library SureSelectXT Human All Exon v5 + UTRs
(Agilent Technologies) for enrichment and sequencing on a Illumina HiSeq2500
instrument (2 × 100 bp, paired end run). The mean coverage of the target sequence
was 50×. The obtained sequence data was analyzed using the Varvis® genomics
platform v1.12.0 (Limbus Medical Technologies GmbH).
IRN1: WES of proband’s DNA was performed. Exomes were enriched with
HiSeq 3000 to an average sequence depth of 91×. Variants were called and
annotated with ANNOVAR40. In accordance with the recessive mode of
inheritance, priority was given to rare biallelic functional variants with allele
frequency <0.001% in public databases, including 1000 Genomes project, NHLBI
Exome Variant Server, Iranome. GME Varome and gnomAD as well as our in-
house database consisting of 14,000 exomes. No plausible compound heterozygous
or homozygous variants were identified in genes previously associated with
neurological phenotypes.
SAU1. Clinical Exome Sequencing (BGI Europe) was carried out using an Illumina
HiSeq 4000 to an average depth of coverage of 150× with automated adapter
trimming of the fastq sequences. DNA sequence quality metrics were carried out
using FASTQC version: 0.11.7. Alignment, quality filtering and variant identifi-
cation were undertaken using commercially available algorithms. Human reference
assemblies were aligned against GRCh37.p13. QIAGEN Clinical Insight—Interpret
software was used in sequence analysis and interpretation. Confirmatory Sanger
test was performed for the index case as well as parent and two siblings.
Statistics and reproducibility. Statistical tests were performed using GraphPad’s
Prism (v7) software. A threshold of p < 0.05 was considered significant. Normality of
distribution was determined using the Shapiro–Wilk normality test with GraphPad’s
Prism (v7). For assays with data displayed with combined sex, it was determined that
there were no sex-dependent differences in phenotype and similar numbers of males
and females were used. Outliers were not removed from phenotypic data. Sig-
nificance was determined using the test indicated in the figure legends. Results are
presented as means ± SD, with individual data points where n < 10.
For reproducibility, NMJs and axon counts were analyzed genotype blind. For
the representative panels Fig. 2a–e are associated with the data collected in Fig. 2f.
Representative images in Fig. 2g–n are associated with the data collected in Fig. 2o.
Representative image panel Supplementary Fig. 4b is associated with data collected
in Supplementary Fig. 4a. Representative image panels Supplementary Fig. 5b–d
are associated with the data collected in Fig. 2p and Supplementary Fig. 5a. The
representative image panel Supplementary Fig. 4k–l is associated with data
collected in Supplementary Fig. 4j. The representative image panels Supplementary
Fig. 8c, d are associated with the data collected in Supplementary Fig. 8e. The
representative image panel in Supplementary Fig. 8f–I are associated with data
collected in Fig. 3e. The representative image panels in Supplementary Fig. 8l, m
are associated with data collected in Supplementary Fig. 8k.
Supplementary Fig. 3a, b are representative of n= 4 WT and n= 4 R86S and
Supplementary Fig. 3c is representative of n= 8 WT and n= 4 R487G biological
replicates. For yeast assays (Fig. 4 and Supplementary Fig. 10), once assay
conditions were defined, experiments were independently replicated successfully at
least 3 times and representative data are shown. For mouse protein assays (Fig. 3a,
Supplementary Fig. 7a, b), protein lysates of at least four mice for each strain and
genotype and multiple organs were tested to confirm lack of NEMF expression. All
attempts were successful.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available as source data in the data
source file. Variant information will be available upon reasonable request and have been
submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/?term=NEMF%5Bgene%
5D)37, AnVil (https://anvilproject.org/) and the European Genome-phenome Archive
(https://www.ebi.ac.uk/ega/home) for public access. Data for genetic matches with NEMF
variants can be found on GeneMatcher19 available to clinicians and researchers
describing patients with variants of interest. The variant summary statistics work makes
use of the following publicly available databases: ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar/?term=NEMF%5Bgene%5D)37, Genome Aggregation database (Gnomad.V2.1.1,
GRCh37/hg19; https://gnomad.broadinstitute.org/)41, Greater Middle East (GME)
Variome (V1) (http://igm.ucsd.edu/gme/)42, Iranome (http://www.iranome.ir/)43, and 1000
Genomes Project (https://www.internationalgenome.org/1000-genomes-browsers)44. Source
data are provided with this paper.
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